A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of Lytixar™ applied
topically to uncomplicated skin infections.
Three dose levels of Lytixar™ (1%, 2% and 5%) versus placebo will be tested.